Tirzepatide Achieves 22.5% Body Weight Reduction in SURMOUNT-1 Phase 3 Trial
Written by
Dr. James K. Okafor, MD
Clinical Research Editor, Obesity Medicine
Medically reviewed by
Dr. Sarah M. Chen, MD, PhD
Medical Director and Lead Reviewer
SURMOUNT-1 Phase 3 data confirms tirzepatide's unprecedented efficacy for obesity treatment. At the highest dose (15mg), 57% of participants achieved at least 20% weight loss over 72 weeks.
Key Findings
- 22.5% mean body weight reduction at the 15mg dose over 72 weeks
- 57% of participants on 15mg achieved 20% or more weight loss
- 91% of participants achieved 5% or more weight loss at the highest dose
- Tirzepatide outperformed semaglutide 2.4mg in cross-trial comparisons
- Significant improvements in cardiometabolic risk factors including blood pressure, lipids, and HbA1c
What Is Tirzepatide?
Tirzepatide is a novel dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide, which acts only on GLP-1 receptors, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism appears to produce synergistic effects on appetite suppression, energy expenditure, and metabolic regulation.
SURMOUNT-1 Trial Design
SURMOUNT-1 was a Phase 3, randomized, double-blind, placebo-controlled trial enrolling 2,539 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity, excluding type 2 diabetes. Participants were randomized to tirzepatide 5mg, 10mg, or 15mg weekly, or placebo, for 72 weeks. All participants received lifestyle counseling. The co-primary endpoints were percentage change in body weight and the proportion achieving 5% or more weight loss.
Unprecedented Weight Loss Results
The results were historic. At 72 weeks, mean weight reductions were 15.0% (5mg), 19.5% (10mg), and 20.9% (15mg) compared to 3.1% for placebo. At the 15mg dose, 57% of participants achieved 20% or more weight loss — a threshold previously only achievable with bariatric surgery. This represents the highest weight loss ever documented for a pharmacological agent in a Phase 3 trial. All doses were statistically superior to placebo.
Comparison to Other GLP-1 Agents
While no direct head-to-head trial has been completed, cross-trial comparisons suggest tirzepatide produces approximately 5 to 7 percentage points more weight loss than semaglutide 2.4mg. The SURMOUNT-5 trial, currently ongoing, will provide the first direct randomized comparison. Indirect evidence from network meta-analyses consistently places tirzepatide at the top of the efficacy hierarchy among approved anti-obesity medications.
Cardiometabolic Benefits
Beyond weight loss, tirzepatide produced significant improvements in cardiometabolic risk factors. Systolic blood pressure decreased by 6.2 mmHg, triglycerides fell by 24.5%, HDL cholesterol increased by 8.4%, and waist circumference decreased by 14.4 cm at the 15mg dose. These improvements are clinically meaningful and suggest tirzepatide may reduce cardiovascular risk through multiple pathways beyond weight reduction alone.
Side Effects and Tolerability
The most common adverse events were gastrointestinal: nausea (31.1%), diarrhea (22.1%), vomiting (12.7%), and constipation (17.6%) at the 15mg dose. Most events were mild to moderate and occurred during dose escalation. Discontinuation due to adverse events was 7.1% in the 15mg group vs. 2.6% for placebo. Serious adverse events were similar between groups. No cases of pancreatitis or thyroid cancer were reported.
Who Qualifies for Tirzepatide?
FDA-approved tirzepatide for obesity is indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. A prescription from a licensed healthcare provider is required. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Sources & References
- 1.SURMOUNT-1 Primary Publication: Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- 2.FDA Approval — Tirzepatide for Obesity: U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. November 8, 2023.
- 3.Network Meta-Analysis: Shi Q, et al. Comparative Efficacy and Safety of Anti-obesity Medications. JAMA Netw Open. 2024;7(1):e2350780.
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.